Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

Background The optimal surgical approach for adenocarcinoma directly at the esophagogastric junction (AEG II) is still under debate. This study aims to evaluate the differences between right thoracoabdominal esophagectomy (TAE) (Ivor–Lewis operation) and transhiatal extended gastrectomy (THG) for AE...

Full description

Saved in:
Bibliographic Details
Published in:Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association Vol. 21; no. 2; pp. 303 - 314
Main Authors: Blank, Susanne, Schmidt, Thomas, Heger, Patrick, Strowitzki, Moritz J., Sisic, Leila, Heger, Ulrike, Nienhueser, Henrik, Haag, Georg Martin, Bruckner, Thomas, Mihaljevic, André L., Ott, Katja, Büchler, Markus W., Ulrich, Alexis
Format: Journal Article
Language:English
Published: Tokyo Springer Japan 01-03-2018
Springer Nature B.V
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The optimal surgical approach for adenocarcinoma directly at the esophagogastric junction (AEG II) is still under debate. This study aims to evaluate the differences between right thoracoabdominal esophagectomy (TAE) (Ivor–Lewis operation) and transhiatal extended gastrectomy (THG) for AEG II. Methods From a prospective database, 242 patients with AEG II (TAE, n  = 56; THG, n  = 186) were included and analyzed according to characteristics and perioperative morbidity and mortality and overall survival (chi-square, Mann–Whitney U , log-rank, Cox regression). Results Groups were comparable at baseline with exception of age. Patients older than 70 years were more frequently resected by THG ( p  = 0.003). No differences in perioperative morbidity ( p  = 0.197) and mortality ( p  = 0.711) were observed, including anastomotic leakages ( p  = 0.625) and pulmonary complications ( p  = 0.494). There was no significant difference in R0 resection ( p  = 0.719) and number of resected lymph nodes ( p  = 0.202). Overall median survival was 38.4 months. Survival after TAE was significantly longer than after THG (median OS not reached versus 33.6 months, p  = 0.02). Multivariate analysis revealed pN-category ( p  < 0.001) and type of surgery ( p  = 0.017) as independent prognostic factors. The type of surgery was confirmed as prognostic factor in locally advanced AEG II (cT 3/4 or cN1), but not in cT1/2 and cN0 patients. Conclusions Our single-center experience suggests that patients with (locally advanced) AEG II tumors may benefit from TAE compared to THG. For further evaluation, a randomized trial would be necessary.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1436-3291
1436-3305
DOI:10.1007/s10120-017-0746-1